Home   >  
GPCR/G Protein
  >  
Ras/Rho

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Ras/Rho

Chemical Structure Cat. No. Product Name CAS No.
AMG-510 Chemical Structure
 BCP33368 AMG-510 2296729-00-3
AMG-510 racemate is a racemic mixture of AMB-510, which is a potent KRAS G12C covalent inhibitor. AMG-510 is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. AMG-510 irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. AMG-510 is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors.
GGTI298 hydrochloride Chemical Structure
 BCP25545 GGTI298 hydrochloride 205590-41-6
GGTI-298 is a potent geranylgeranyltransferase-I (GGTase-I) inhibitor with potential antitumor actrivity. GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
BI-2852 Chemical Structure
 BCP33277 BI-2852 2375482-51-0
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) because it binds to a different pocket present in both the active and inactive forms of KRAS.
NSC 23766 trihydrochloride Chemical Structure
 BCP33238 NSC 23766 trihydrochloride 1177865-17-6
NSC 23766 trihydrochloride is an inhibitor of Rac1 activation.
Antineoplaston A 10 Chemical Structure
 BCP32894 Antineoplaston A 10 91531-30-5
Antineoplaston A 10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.
CCG-222740 Chemical Structure
 BCP31985 CCG-222740 1922098-69-8
CCG-222740 is a potent and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor. CCG-222740 also is a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis.
ZT-12-037-01 Chemical Structure
 BCP31626 ZT-12-037-01 2328073-61-4
ZT-12-037-01 is a potent, selective, ATP-competitive STK19 inhibitor. ZT-12-037-01 effectively blocks oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo.
BI-2852 Chemical Structure
 BCP31539 BI-2852 BI-2852
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity.
MRTX849 Chemical Structure
 BCP31538 MRTX849 2326521-71-3
MRTX849 is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. MRTX849 covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction.
(rac)-Antineoplaston A10 Chemical Structure
 BCP31010 (rac)-Antineoplaston A10 77658-84-5
(rac)-Antineoplaston A10 is the racemate of Antineoplaston A10.
123下一页末页共 48 条记录 1 / 5 页 
0086-13720134139